Demethyleneberberine

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Basic and Applied Basic Research Foundation of Guangdong Province and 3 more

Model organisms1

Outcomes

Lifespan

upin worms1

1 study

Demethyleneberberine extends lifespan in worms.
“DMB obviously extend the lifespan of C. elegans under conditions of heat and oxidative stress”
Model organismsunder conditions of heat and oxidative stress
Demethyleneberberine alleviates cellular senescence of human fibroblasts by directly activating FEN1
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie18 Mar 2026

FEN1

upin human cells1

1 study

Demethyleneberberine activates FEN1 in human cells.
“DMB was able to directly activate FEN1”
Cellsin senescent MRC-5 cells
Demethyleneberberine alleviates cellular senescence of human fibroblasts by directly activating FEN1
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie18 Mar 2026

Latest

1 in 12 months

Biomedicine & Pharmacotherapy20 Mar